Callouts & quotes from 10,384+ activist slides

""Based on the Company Data Analysis, the total addressable market for our core solutions was less than 25% penetrated in 2020?" — DV Prospectus, p. 4; "Penetrated, safe to say, 95% of them use some serious verification... it's very penetrated. Now it is not a lot of green. It's more winning over clients that may use IAS... But when it comes to just picking up new clients that have no idea what verification with DV is, I would say those days are long gone, at least clients that you want to work with, so to speak." — Former Sales Executive at DoubleVerify"

"During 2016, expenses were reclassified from sales and marketing expenses to cost of revenue and general and administration for one of our businesses. The expenses moved to cost of revenue are traffic acquisition costs in nature and more appropriately classified as costs of revenue, and the other costs more appropriately classified as general and administrative expenses. For 2015, $994,000 was reclassified from sales and marketing to cost of revenue and $290,000 was reclassified from sales and marketing to general and administrative expense. — 2016 10-K"

""The transaction would have been just another [Stryker] tuck-in but we believe the transaction has broader implications for [Stryker] and its plans in spinal robotics." — Analyst Zimmerman, BTIG. "Cardon robotics. So that the elements they were gonna do robotics within that there's, you know, it was a bit of a concept when we acquired it." — Former Stryker Professional Familiar With Cardan. "I can't predict that. Robotics is very difficult to predict, David. I'm just going to take a pass on that." — CEO Lobe In Response To Cardan Availability by NAS 21."

"“TransMedics is taking care of literally everything...actually I’m unaware if the decision is even made by the transplanting surgeon because once TransMedics takes the organ from the donor...they can make the call right then and there...if you have a lousy organ...and they’re already worried...and it doesn’t look good...they should discard it right then, but they don’t...what I have heard is that once the organ goes into the hands of TransMedics...the receiving team has very little input on anything that happens....” — Senior medical employee at OrganOx"

""In the first quarter of 2020, we adopted, using the modified retrospective approach, amended accounting guidance that required credit losses on financial instruments, including trade receivables, to be measured based on an expected credit loss model instead of the incurred loss model. The expected credit loss model requires us to consider forward-looking information to estimate our allowance for credit losses. Our adoption of this guidance did not have a material impact on our financial position, results of operations or cash flows." — 2020 10-Q, p. 6"

""Pioneer management has delivered [a] text book repositioning of a portfolio previously spread across more than seven countries to become a 100% U.S. focused resource player." — Bank of America Merrill Lynch (October 2, 2012); "We believe that Anadarko has transformed itself from a company with an inferior asset base and questionable capital allocation success into a company with a strong asset base. The company continues to deliver at-or-above expectations and we believe that it can continue to surprise to the upside.." — Lehman Brothers (May 7, 2008)"

""The Company had capital expenditures with Floor & Decor Holdings, Inc., a specialty retail vendor in the flooring market. These capital expenditures amounted to $0.1 million, $0.6 million, and $0.4 million in fiscal 2023, fiscal 2022, and fiscal 2021, respectively, and were recorded as property and equipment, net on the consolidated balance sheets. During these fiscal years, certain members of the Company's board of directors either served on the board of directors or as an executive officer at Floor & Decor Holdings, Inc." — Boot Barn Proxy Statement"

"“strive to meet the same standards of transparency that we ask of the companies our clients are invested in” and to “report Scope 1, Scope 2, and Scope 3 emissions for our corporate operations” — CEO Larry Fink, ‘Dear Client Letter’, 2021. “we said, and I have always been loud on this, we are not going to support Scope 3 at this time” and “I have no problem in doing Scope 1 and 2. But we have always said that Scope 3 is forcing big companies, banks, and asset managers to be the environmental police” — CEO Larry Fink, Bloomberg’s interview, 2 June 2022."

""We believe that the market is giving a sizable discount to the value of its cash and investment assets which account for 44% of the current market cap due to poor capital management." — JPMorgan, June 15, 2015; "With the newly created incentive to pay out more of it earnings through dividends, all investors in SEOC [newco] would benefit." — Credit Suisse, January 12, 2015; "If Samsung Group were to restructure into a holding company, our case studies show it would be likely to have positive share price implications." — Deutsche Bank, November 3, 2014"

""The Company's reported effective tax rate was 21.4% in 2018, 34.5% in 2017, and 23.8% in 2016. As discussed below, the provision for income taxes included charges of $3.6 million in 2018 and $72 million in 2017 related to the Tax Cuts and Jobs Act ("the Act") which had the effect of increasing our effective tax rate by 0.6% and 12.5% in 2018 and 2017, respectively. The 2018 effective tax rate also included a benefit of 0.7% associated with the one-time gain related to the settlement of the Biotix contingent consideration." — Mettler-Toledo SEC Filing"

""It's not all going to be Software as a Service, I've met no CIOs who think that" — Bob Beauchamp (2007, Interview with The Australian); "SaaS initiative includes our new BMC Remedy OnDemand Solution, which provides customers with a full industry leading service management offering delivered as a service" — Bob Beauchamp (Q4 2010 Earnings Conference Call); "We were then late, unfortunately, as you well know, to the SaaS market. So when it turned to SaaS, we didn't have a great answer at the same time" — Bob Beauchamp (Q4 2012 Earnings Conference Call)"

"The parties hereto desire to amend the Credit Agreement: (i) to increase the aggregate Revolving Credit Commitments from $50,000,000 to $75,000,000; (ii) to add KeyBank National Association “KeyBank”, by joinder, as a Lender under the Credit Agreement, with a Revolving Credit Commitment of $25,000,000; (iii) to permit the Borrowers to grant a subordinate purchase-money security interest to Merial LLC (“Merial”); and (iv) to make various technical corrections and other modifications, all as set forth below. — PETQ Q2 FY18 10-Q: Amended Credit Agreement"

"“For example, you just took the elevator from the lower level elevator, and at the entrance of the elevators there are three LCD screens, this is considered one location. There are also screens at the upper level elevators. The lower level elevator is considered one location and the upper level elevators is also considered to be one location. There are two locations in this building, each location may have one, two or three screens. 'Location' really means the spots in one specific building. There are 70,000 LCD screens nationwide.” — FMCN Salesperson"

"On January 1, 2021, the Company acquired substantially all of the net assets of Base Commerce LLC ("Base"), a technology-driven payment processing company specializing in bank card and automated clearing house payment processing solutions. The purchase price for this acquisition totaled $92,678. The remaining amount consists of a contingent consideration of $3,004 which is contingent upon meeting certain performance metrics. ... Acquisition costs of $268 have been expensed during the nine months ended September 30, 2021. — Nuvei Q3'21 Financials, p.9"

""At the end of the day, it's just a label, it's just a label. There's no rocket science around paper that you coat with an adhesive." — Former Avery VP, 7 Yr Veteran. "RFID is one of the few upside growth areas in RBIS. I left because there wasn't enough upward mobility." — Former Business Development Manager, RFID. "The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of one reporting unit in the IHM reportable segment is a critical audit matter..." — 2019 Critical Audit Matter."

"Although there is some considerable overlap among analysts as to what might be appropriate adjustments to Funds From Operations that would make it a better measure of dividend paying capacity, NAREIT believes that there is not adequate consensus among preparers and users of the REIT financial statements to allow agreement on a single definition of Funds (Cash) Available for Distribution or AFFO. Further, NAREIT does not believe that there is a single measure of distributable cash that is consistently applicable to all REITs. — NAREIT 2002 White Paper"

"We previously utilized retrospective RNA genetic testing for specific variants in Ambry's Translational Genomics (ATG) lab. With this approach, we observed two critical limitations. First, deep intronic pathogenic/likely pathogenic variants that were clinically actionable still remained undetected. Second, there was a 90% lost to follow-up rate for patients who were offered additional RNA studies due to the need to send in an additional sample. Therefore, it is more advantageous to offer RNA testing concurrently with DNA testing. — Ambry Genetic Blog"

""Importantly, we'll have strong cash flow generation as a result of this transaction, about $1 billion in operating cash flow in the second year and accelerating...." — Acquisition of Bayer by Elanco 8/20/2019; "Looking at our returns, Elanco will generate significant cash flow and exercise strong cash management to pay down debt, reducing interest cost as quickly as possible, increasing optionality of the business and most importantly delivering double digit EPS growth to unlock value for you, our shareholders." — Elanco 2020 Investor Day 12/15/2020"

"“strive to meet the same standards of transparency that we ask of the companies our clients are invested in” and to “report Scope 1, Scope 2, and Scope 3 emissions for our corporate operations” — CEO Larry Fink, ‘Dear Client Letter’, 2021. “we said, and I have have been loud on this, we are not going to support Scope 3 at this time” and “I have no problem in doing Scope 1 and 2. But we have always said that Scope 3 is forcing big companies, banks, and asset managers to be the environmental police” — CEO Larry Fink, Bloomberg’s interview, 2 June 2022."

"The discretionary components of our business, which are the most affected by general economic conditions, have been challenged by cautious consumer spending on big ticket items like swimming pools and outdoor living projects resulting in sales of building materials declining 11% for the year compared to the same period in 2023. We now believe that new pool units could be down 15% to 20% in 2024, and remodeling activity for 2024 may be down as much as 15% compared to our previous estimate of flat to down 10% compared to 2023. — Pool Corp Press Release"

"I don't know what they own the IP on if it's the cell channels or the process—the optofluidics thing to move a cell. So, it's hard for me to say. Here's the thing, there are so many different ways that modern nano and micro-fluidics can come up with something that would compete with Berkeley Lights that could be cheaper... If people start using it, then we'll come up with something that costs a quarter of what this costs, and we'll low-ball them because all these pharma authorities spend $20-30 million with us every year. — Bristol Meyers employee #1"

"All the differences between the unaudited accounts and AR that have been referred to in the CLSA’s Report, are essentially re-classification changes between subsidiary accounts in different jurisdictions as compared to Group consolidation; and/or re-classification between line items within the Group accounts. However, this does not lead to any inaccuracy in reported profits, net assets or point to any lack of internal controls, as has been stated in the CLSA report. None of these adjustments have any P&L impact. — Olam response to CLSA Analyst Report"

"There was a lot of bias in the Nevro pivotal trial. We had to talk people into the study, and then they'd go home and pray they got the new stimulator and then they'd get the old one and be grumpy. It wasn't a pristine way to set up a study. I hope the study wasn't bs. It does bother me. I'm going to say it was done honestly. It's just that as the study unfolded, I could see the bias. I'm different than most guys Nevro markets to. I need higher evidence. I haven't switched my patients over to Nevro. — KOL and key player in the SENZA-RCT pivotal trial"

"“We did talk to Soleno when they were doing their Phase 3 trial...we did see the data, and we did see the number of people who had diabetes. I do know at least two families that dropped out of the Vykat study, and both of their kids got diabetes, and they were not pre-diabetic. That’s concerning to me. And both of them are still now struggling with controlling diabetes. I think that people who take this drug —you now have another problem that you have to treat, that’s a bigger problem —” — KOL in the PWS field; involved with Soleno’s clinical program"

"On July 14, 2025 (the “Signing Date”), Faraday Future Intelligent Electric Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”). Pursuant to the Purchase Agreement, the Company has agreed to sell, and the Investors have agreed to purchase, in two closings, for an aggregate purchase price of $82 million, (i) certain senior unsecured convertible notes in the aggregate original principal amount of $82 million (the “Unsecured Notes”) — 8-K filing."

"“... Oasis believes Kao can become a competitive global player and emulate the success of companies such as Beiersdorf and L'Oréal... Through a committed focus on personal care and cosmetics, Oasis believes Kao can become a competitive global player and emulate the success of companies such as Beiersdorf and L'Oreal. Kao needs a leadership that can articulate an ambitious growth strategy built on a cohesive overseas growth plan focused on a core set of brands and backed by a credible marketing, branding and distribution strategy.” — Oasis Management"

"“Once you become a Distributor there is a really good thing called Management Fees [consulting fees]. In Herbalife, the biggest part of our pay comes from Management Fees. Some people earn 100,000 RMB to 200,000 RMB per month. It is not possible to earn this kind of money just from retail profits.” — Ms. Ping, Guangzhou; “Even if I don’t earn money from any personal sales I still earn hourly consulting pay.” — Ms. Chen, Guangzhou; “Earning 30% of retail profits is not very much. But the consulting fee paid by Herbalife is very high.” — Mr. Hu, Hefei"

"We compute our average days sales outstanding, or DSO, as of a given date based on our trade receivables balance at the end of the period, divided by the average daily revenue of the trailing three-month period. We compute our average days payable outstanding, or DPO, as of a given date based on our trade payables balance at the end of the period, divided by the average daily cost of operating expenses over such period, excluding depreciation, amortization, and certain other costs that are excluded from Adjusted EBITDA. — DoubleVerify Holdings, Inc."

"As part of Short-term receivables - controlled or controlling person, significant influence, the Company reports receivables from ORCO PROPERTY GROUP S.A. as of December 31, 2017. On account of remuneration for assignment of receivables in the amount of 461,382 thous. CZK (2016 - CZK 0 thousand). The subject of the assignment was a receivable from a third party, which was reported under Other short-term receivables in the amount of 442,354 thousand as of December 31, 2016. CZK and outstanding interest for 2017. — CPI Hotels Financial Statements 2017"

""Intel uses pellicles. TSMC has had a mixed history of using pellicles or not using pellicles, but for the most part, hasn't been." — Longtime semiconductor consultant recently working for Lasertec; "One other thing I would point out is on the High-NA side. If you've been reading the news reports, it looks like TSMC is not going to push very hard on High-NA. What they've decided to do, apparently, is do multiple patterning standard EUV rather than trying to do single pattern High-NA." — Longtime semiconductor consultant recently working for Lasertec"

"When Xylem spun out of ITT it was not integrated. ITT had internal businesses competing with each other. When it spun out the number of ERP CRM CPQ systems where like 50 to 70 different systems across the Company. Legal entities, much higher than that. Initially, we were a self-help story. Everyone loved it for a while. We made progress, but there is a lot still there. The question is how does Xylem find a way to live with the complexity vs. getting to one system. Very expensive and a lot of change management to fix things. — Former Xylem Executive"

"Cost of revenue primarily consist of professional fees and materials under the Managed Services model and credit card processing fees, including merchant fees. — Prospectus, p. 70; Porch provides ERP and CRM software to a wide variety of home services companies. Those companies can pay us with typical software fees or we really encourage those companies to pay us by providing us access to their consumer, to their homebuyers, where we then generate B2B2C transactional revenues as we help those consumers with key services for their home. — Transcript"

""And here's the other thing you have to be very cautious about... when they sell an engine, they're not selling an engine. They're selling [three] modules. So the, The Module Factory numbers are much higher than what real [customer demand for the Factory] is." — Consultant A. "Well, I'm no longer there. But I could tell you that was the line of thought when I was there...so what I'm suggesting is that that is still happening...there would be more of those modules [that] would be attributed to engine sales than to true module swaps." — Consultant A."

"No, this started in 20... in 2015 it already started. Because then we were doing O2O [online to offline], we helped many institutes attract more traffic. At that time there were few students, but we want the teachers to feel that there were many, especially when we just started, for example just five students might have signed up and the remaining 500 were robots, letting the traffic volume become very big, going online listening to the class, it let them feel that the platform’s volume was huge. Starting from 2015 this was there. — Former Employee"

"Yeah. They should not be allowed to have access to Donor Net. And I know that really certainly pisses off some OPOs when, for example, you get a situation where a transplant center turns down a liver that TransMedics has arrived to recover. And the TransMedics people start calling around to other surgeons, other programs, saying there’s a liver out there. Do you want to take it? And the OPOs are like, you can’t do that; that’s our job. We’ll allocate the organ; don’t be making these phone calls. — Transplant surgeon at a high volume academic center"

""We did [the CoreWeave deal] because we all got caught with the hit called Chat GPT and Open AI APIs, right? We were completely, I mean like, yeah, it was, it was impossible... And that is a one-time thing and then now it's all catching up and you know, so that was just more about trying to get caught up with demand." — Satya Nadella, Microsoft CEO, BG2 Podcast, December 2024; "Microsoft has had time to pivot; it's been two and half years since ChatGPT hit... they don't need to depend on other people anymore" — Former Principal Architect at Nvidia."

""Haphazard efforts at omnichannel can destroy value" and "Offering a compelling omnichannel experience used to be the bleeding edge of retail. Now it’s a requirement for survival." — McKinsey On Retail Omnichannel. "Moving to our third initiative, strengthening our omnichannel leadership. In the third quarter, our e-commerce sales declined 11.5%. Our online channel has felt pressure due to less efficient online marketing spend, partly caused by an increase in digital spend by a handful of vendors and competitors." — CEO James Conroy, Jan 31, 2024."

"“It’s their Achilles’ Heel at the same time.” — Ex-senior executive of Gen9; “I have thought so for many years.” — Ex-senior executive of Gen9; “Instead of using the minimum number of spots to make a gene, they over-engineer or over-produce in order to guarantee that they’re going to get a gene and even with that, they still only have a 90% delivery rate or something like that... there’s no way that you can sell a gene at 10 cents a base pair or 5 cents a base pair or to Ginkgo at 1.5 cents and hope to be profitable.” — Ex-senior executive of Gen9"

"“Because they can’t get to scale. If you’re designing a new hybridization capture panel, you’re going to test out a whole bunch of different designs... However, especially in a regulated space like oncology, once you’ve decided on your design, you want to repeat it over the course of thousands and thousands of patients. So, you need not small femtogram amounts of each of the oligos that go into that panel. You need pico to nanogram amounts of that, that you can then divide out onto many, many panels.” — IDT ex-regional sales manager, left recently"

""At current valuation levels, by simply marking to market the value of non-refining businesses, we estimate one can create the MPC refining business for effectively free before even incorporating the upside from IMO 2020." — Goldman Sachs, March 19, 2019; "We see discounted value in MPC with the stock trading in line with many of its peers on 2020 EBITDA despite its corporate structure with retail and midstream deserving a premium. However, debate has centered on investors' confidence in MPC's earnings achievability." — Morgan Stanley, May 9, 2019"

"It is called an index universal life insurance policy. It is cash value on steroids. — WFG Recruiter; You can never get that in the bank. It's gonna never, ever, ever lose money, my friend. Never in your life. And you will never ever pay taxes. — WFG Recruiter; I-U-L remember, I told you to write down index universal life. If you can qualify for that baby, your future is brighter than the sun. — WFG Recruiter; I could not tell you this in all fidelity with the license, and keep my keep my license. If I wasn't telling you the truth. — WFG Recruiter"

""We also believe the rationale for consolidation in coatings remains strong (US peers commented on the need for large scale M&A at GS Basic Materials Conference earlier in May)." — Goldman Sachs research, 6/4/18; "...[we] continue to note that with the coatings industry at the cusp of another round of global consolidation, Akzo is the key strategic asset." — Deutsche Bank research, 4/24/18; "The global coatings sector is consolidating and AXTA could be an acquisition candidate, which could be an upside risk to the shares." — Citi research, 4/19/18"

""In that meeting, Mr. Bodner reiterated his position that he believed there is no incremental value that could be generated from separating CES and CIS, that Verint's customers do not want to transition to the cloud, and that Verint had no intention to pursue a cloud-centric strategy for CES." — Neuberger Berman Proxy Filing; "As we've discussed [on] prior calls, enterprise customers have been interested in a move to the cloud and what we've seen lately is that they've accelerated the cloud adoption and cloud purchases." — Dan Bodner – CEO, Verint"

"I heard anecdotally that Nevro was paying $1,000 an hour. Question: Do you think what they're doing is essentially a kickback or an inducement? "Well, I'm not an ethicist but that certainly seems to be the case. [laughs] I mean, a hundred percent. Hundred percent." — KOL #1; "Yeah, because they're just trying to feed their kids. They're saying, "If you do this, we'll take care of you." ... Question: Have you ever observed the Nevro reps do anything illegal or what you thought may cross the line, or is it just kind of gray? "All the time"" — KOL #2"

"“We did talk to Soleno when they were doing their Phase 3 trial...we did see the data, and we did see the number of people who had diabetes. I do know at least two families that dropped out of the Vykat study, and both of their kids got diabetes, and they were not pre-diabetic. That’s concerning to me. And both of them are still now struggling with controlling diabetes. I think that people who take this drug —you now have another problem that you have to treat, that’s a bigger problem —” — KOL in the PWS field; closely involved with Soleno’s trial"

"“it’s like a horse pill”; “they’re going to chew it”; “I was concerned because the fourth most common cause of death...is choking...they can’t swallow...their choking reflex is poor...it’s a problem...I saw that...they would chew, those that I witnessed...concerns with that big pill....make sure your child doesn’t choke...after I saw the size of that pill and said, oh my God, they’re never going to swallow this...I guess if you chew it, you swallow it in smaller pieces.” — Trial investigator and physician; one of the leading KOL’s in the PWS field"

"“Well, it's amazing you've done all that good investigation. It's very concerning...I feel like the truth eventually comes out... I've seen this before... I've learned to be cautious...it's so super expensive...and they didn't have weight loss data...that is concerning to me”; “you obviously are 20 steps ahead of me...I don't think we've started anyone on this in our whole practice...we may be foolishly just applying for it...it's very strange...you're quite knowledgeable on this.” — Pediatric oncologist, Children's Hospital of Philadelphia (CHOP)"

""Stryker is reducing gross margin expectations. We're now 18 months into COVID maybe two years. Why do you think is the reason it's taken so long for them to admit some of the supply chain challenges?" — Spruce Point Question. "So what's been happening here is just indicative of the larger ecosystem in terms of all the supply chain challenges that are ongoing... I think that's now playing catch up where, it's just been hard for Stryker to keep up with the level of issues going on with their supply base." — Former Stryker Supply Chain Professional."

"Datavault AI will mint experiential Valor tokens via a proprietary, military-grade deployment co-developed with Burke, connecting service men and women to their benefits, services, associations, unions, clubs, coupons, discounts and promotions offered by private sector businesses. Through Burke Products, an exclusive licensor of Datavault AI technology under a U.S. sole-source government contract—awarded only when no other supplier exists—Datavault AI's patents ensure unrivaled exclusivity in the U.S. and internationally. — DVLT August 25, 2025 PR"

"As Gary transitions to the Executive Chairman role, we are completely aligned in terms of the direction of the company. There are things, of course, that we want to work on, but this is not a change to Southwest Airlines, 90 degrees either direction. We're extremely aligned. We're not reinventing the company post-pandemic. It's quite the opposite... And I just want to stop and express my gratitude to my friend, Gary Kelly. He's been my sponsor, my mentor for 34 years. You couldn't have a better one. He's my friend. — CEO Bob Jordan, December 2021"

"...a GROUP OF 25-30 PEOPLE came into your restaurant unannounced. Your employees WELCOMED US WITH A SMILE, and we were seated quickly. Our main server was Terrence. He was PHENOMENAL. He was CHEERFUL, FRIENDLY AND EXTREMELY HELPFUL, and our service was fast and FLAWLESS. Our boys are 14, and we were in town for a SOCCER TOURNAMENT. Your servers ENGAGED with them and handled our table with ease. YOUR TEAM EXCEEDED MY EXPECTATIONS of large unannounced groups in restaurants. Thank you so much. KEEP DOING WHAT YOU ARE DOING. — Anonymous Guest Comment"

""I think their main issue is scalability. They cannot produce large quantities of their single pieces of DNA, and that causes all kinds of downstream application problems because they have to compensate for that in one way or another through methods like amplifying the material that they do have and tiling in the case of NGS. And consistency and turnaround time for double-stranded DNA constructs and keeping mutation rates down. They have repeatedly higher mutation rates in their double-stranded DNA." — IDT ex-regional sales manager, left recently"

"As Gary transitions to the Executive Chairman role, we are completely aligned in terms of the direction of the company. There are things, of course, that we want to work on, but this is not a change to Southwest Airlines, 90 degrees either direction. We're extremely aligned. We're not reinventing the company post-pandemic. It's quite the opposite... And I just want to stop and express my gratitude to my friend, Gary Kelly. He's been my sponsor, my mentor for 34 years. You couldn't have a better one. He's my friend. — CEO Bob Jordan, December 2021"

"“Solid provider, but not innovative.” — Client 1; “MSCI was an early mover on the climate space, they need to keep innovating to keep their position, the space has become much more crowded.” — Client 2; “MSCI is a leading index provider who has improved its analytics offerings. It needs to improve its ESG and climate product to better compete in the marketplace.” — Client 3; “I think that the value could be improved with additional customizability.” — Client 4; “MSCI works well but there is not much difference from them and JP Morgan.” — Client 5"

""The issue with the circular revenue with Synlogic, basically, they provided Synlogic $30 million, Synlogic turned around and paid it to them, so they were registering their own money as revenue, and then they tried to make a strain for Synlogic, and it didn't work, and then they had to go to Zymergen and get the strain. I think just two days ago; the clinical trials showed that the Zymergen strain was effective." — Former employee in a managerial role; "It's biology. Nobody even at Ginkgo can say whether it will or not" — Former Ginkgo employee."

""I question what their future looks like because if they don't have a strategic initiative that is going to gain them market share, it's going to be just hand-to-hand combat in the spinal cord stimulation space. I don't see the market share shifting a lot." — Longtime SCS executive; "I don't think he has an appreciation for what motivates the spinal cord stimulator customer." — Longtime SCS executive; "I know for a fact, on the inside, Grossman has said he's scratching his head over why the stock has done what it's done." — Longtime SCS executive"

"“The market will be flat. It should have been flat last year. There are just a lot of players in the market and pricing is eroding in the space. ASC’s couldn’t use Nevro because they kept the price really high. Grossman said screw that. We want as much market share as possible. Nevro started price reductions in the space after Grossman came in. Nevro drastically lowered pricing to get as much share as possible in 2019. It’s cutting your nose off to spite your face. Cutting prices will lower reimbursements over time.” — Medtronic territory manager"

"“Yeah, it’s crazy. They’ll deny it. There are times where—again, we might have that donor in Reno—perhaps they have a machine available here, and there are times when we have an OR and three planes land for the TransMedics operation. One brought the machine from San Ramon. The other one, they sent a surgeon in from Phoenix, and the other plane brought in an OCS specialist, their technician, to operate the machine from San Diego. It is crazy what they’re doing. I don’t understand.” — Executive at a leading West Coast OPO, longtime industry veteran"

"“...just how unqualified the people are that are running their devices...those should be nurses...they’re not even people from the operating room, which puts everybody in a pinch....these people are coming in and they don’t know...the other teams...have to help them...they’re clearly not prepared...one of my co-workers who is not qualified in any way, shape, or form...she’s still working for TransMedics...she’s not qualified to be pulling or pushing medications.” — Organ procurement technician at a high volume Northwest academic transplant center"

"“I would say that many of my patients are on Facebook groups and so on...they've been excited for it...they've been wanting to start it as soon as it was released” — Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center. “I didn't attend any of the Vykat sessions.. I didn't personally talk to anybody about Vykat at the conference...” — Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center."